Cue Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	16.38	27.14	22.46	48.51	51.61	64.37
Short-Term Investments	-	-	-	-	24.68	-
Cash & Short-Term Investments	16.38	27.14	22.46	48.51	76.29	64.37
Cash Growth	24.69%	20.82%	-53.71%	-36.41%	18.52%	-24.15%
Accounts Receivable	5.35	5.55	0.95	1.7	0.06	3.14
Other Receivables	1.9	1.9	-	-	-	-
Total Trade Receivables	7.25	7.45	0.95	1.7	0.06	3.14
Other Current Assets	2.76	2.4	1.73	1.24	0.84	0.95
Total Current Assets	26.39	36.98	25.14	51.45	77.19	68.47
Net Property, Plant & Equipment	3.61	4.32	4.84	7.12	10.7	11.92
Other Long-Term Assets	0.88	0.91	2.21	2.96	3.39	3.01
Total Assets	30.88	42.21	32.19	61.53	91.28	83.4
Accounts Payable	3.33	3.95	2.82	3.5	2.73	2.59
Accrued Expenses	1.5	1.61	2.91	4.14	3.55	4.62
Current Portion of Long-Term Debt	-	-	4.33	3.96	1.96	-
Current Portion of Leases	1.56	1.91	3.54	3.37	3.3	4.93
Unearned Revenue	-	5.34	0.09	2.11	-	0.65
Other Current Liabilities	1	0.69	-	-	-	-
Total Current Liabilities	7.39	13.49	13.69	17.08	11.55	12.79
Long-Term Debt	-	-	-	4.2	8.04	-
Long-Term Leases	1.88	2.29	1	3.16	6.02	5.12
Total Long-Term Liabilities	1.88	2.29	1	7.36	14.05	5.12
Total Liabilities	9.27	15.78	14.69	24.45	25.6	17.91
Common Stock	0	0.1	0.06	0.05	0.04	0.03
Additional Paid-in Capital	395.25	394.8	359.3	338.23	316.19	262.91
Accumulated Other Comprehensive Income	-	-	-	-	-0.1	-
Retained Earnings	-373.64	-368.47	-341.86	-301.19	-250.46	-197.45
Shareholders' Equity	21.61	26.43	17.5	37.09	65.68	65.49
Total Liabilities & Equity	30.88	42.21	32.19	61.53	91.28	83.4
Total Debt	3.44	4.2	8.88	14.7	19.32	10.05
Net Cash (Debt)	12.94	22.94	13.58	33.82	56.97	54.32
Net Cash Growth	115.25%	68.88%	-59.84%	-40.64%	4.89%	-30.11%
Net Cash Per Share	3.44	7.26	7.23	22.17	47.95	52.09
Book Value	21.61	26.43	17.5	37.09	65.68	65.49
Book Value Per Share	5.75	8.37	9.32	24.32	55.27	62.80
Tangible Book Value	21.61	26.43	17.5	37.09	65.68	65.49
Tangible Book Value Per Share	5.75	8.37	9.32	24.32	55.27	62.80

SEC Filings: 10-K · 10-Q